|
Aerovate Therapeutics, Inc. (AVTE) DCF Avaliação
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Aerovate Therapeutics, Inc. (AVTE) Bundle
Procurando avaliar o valor intrínseco da Aerovate Therapeutics, Inc.? Nossa calculadora DCF (AVTE) integra dados do mundo real com extensos recursos de personalização, permitindo refinar suas previsões e aprimorar suas opções de investimento.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | .0 | -8.9 | -23.0 | -53.2 | -81.3 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | 3.3 | .0 | .0 | .1 | .1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -3.3 | -8.9 | -23.0 | -53.2 | -81.4 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 3.5 | 4.6 | 167.4 | 129.2 | 122.4 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .5 | .6 | 1.2 | 2.6 | 2.4 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | -.2 | -.2 | -.1 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | -0.07420659 | -0.07420659 | -0.07420659 | -0.07420659 | -0.07420659 | -0.07420659 | -0.07420659 | -0.07420659 | -0.07420659 | -0.07420659 |
| EBITAT | -3.3 | -8.4 | -23.0 | -53.3 | -81.5 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | .5 | -8.3 | -22.6 | -52.0 | -81.7 | -2.4 | .0 | .0 | .0 | .0 |
| WACC, % | 8.64 | 8.64 | 8.64 | 8.64 | 8.64 | 8.64 | 8.64 | 8.64 | 8.64 | 8.64 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -2 | |||||||||
| Net Debt | -23 | |||||||||
| Equity Value | 21 | |||||||||
| Diluted Shares Outstanding, MM | 26 | |||||||||
| Equity Value Per Share | 0.78 |
What You Will Receive
- Customizable Excel Template: A fully editable Excel-based DCF Calculator featuring pre-filled financial data for Aerovate Therapeutics, Inc. (AVTE).
- Accurate Data: Historical performance metrics and forward-looking projections (highlighted in the yellow cells).
- Assumption Flexibility: Modify key forecast parameters such as revenue growth, EBITDA %, and WACC.
- Instant Calculations: Quickly assess how your inputs affect Aerovate's valuation.
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
- Intuitive Layout: Organized for clarity and ease of navigation, complete with step-by-step guidance.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Aerovate Therapeutics, Inc. (AVTE).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to the biotech sector.
- Customizable Forecast Assumptions: Easily modify growth rates, research and development expenses, and discount rates.
- Integrated Financial Ratios: Assess profitability, leverage, and efficiency ratios relevant to Aerovate Therapeutics, Inc. (AVTE).
- Interactive Dashboard and Charts: Visual representations highlight essential valuation metrics for streamlined analysis.
How It Works
- Step 1: Download the prebuilt Excel template featuring Aerovate Therapeutics' (AVTE) data.
- Step 2: Navigate through the pre-filled sheets to grasp the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly view updated results, including Aerovate Therapeutics' intrinsic value.
- Step 5: Make well-informed investment decisions or create reports based on the outputs.
Why Choose Aerovate Therapeutics Calculator?
- Accuracy: Utilizes real Aerovate financial data for precise calculations.
- Flexibility: Tailored for users to easily adjust and experiment with inputs.
- Time-Saving: Avoid the complexities of constructing a financial model from the ground up.
- Professional-Grade: Crafted with the expertise and detail expected at the CFO level.
- User-Friendly: Intuitive design makes it accessible for all users, regardless of financial background.
Who Should Use This Product?
- Biotech Students: Understand drug development processes and apply them using real-world case studies.
- Researchers: Integrate advanced models into your studies or clinical trials.
- Investors: Evaluate your investment strategies and analyze valuation trends for Aerovate Therapeutics, Inc. (AVTE).
- Market Analysts: Enhance your analysis with a comprehensive, customizable financial model.
- Healthcare Entrepreneurs: Discover how large biotech firms like Aerovate Therapeutics are assessed and valued.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Aerovate Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Aerovate Therapeutics, Inc. (AVTE).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.